Benchmarking Scope 3 Emissions Reporting Across the Pharmaceutical Industry

With mandates like the EU’s Corporate Sustainability Reporting Directive, which came into force in 2024 for sectors like the pharmaceutical industry, the scope of sustainability reporting for large organisations is continuing to grow.

Comprehensive and transparent reporting helps companies identify areas for improvement, set targets, and track progress in reducing their environmental impact. To date, they have mostly been focusing on initiatives to reduce Scope 1 and Scope 2 emissions. Scope 3 upstream emissions on the other hand remain hard to target and challenges remain in standardising GHG reporting across the industry.

Download this white paper to explore:

Key sustainability frameworks and initiatives shaping the pharmaceutical sector's approach to sustainability
Industry-wide challenges and complexities of supply chain Scope 3 emissions reporting
Comprehensive data analysis of Scope 3 emissions data from the top 25 pharmaceutical and biotech organisations.
Industry trends and future outlook

This white paper is an essential resource for pharmaceutical industry professionals, sustainability experts, and anyone interested in the intersection of healthcare, supply chain sustainability, and environmental responsibility.

Explore LSP Integrations Solutions

Benchmarking Scope 3 Emissions Reporting Across the Pharmaceutical Industry

Download this white paper to explore:

Download the White Paper